-
1
-
-
0021346853
-
Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22
-
Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984;36:93-9.
-
(1984)
Cell
, vol.36
, pp. 93-99
-
-
Groffen, J.1
Stephenson, J.R.2
Heisterkamp, N.3
de Klein, A.4
Bartram, C.R.5
Grosveld, G.6
-
2
-
-
0021811764
-
Structural organization of the bcr gene and its role in the Ph' translocation
-
Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveld G. Structural organization of the bcr gene and its role in the Ph' translocation. Nature 1985;315:758-61.
-
(1985)
Nature
, vol.315
, pp. 758-761
-
-
Heisterkamp, N.1
Stam, K.2
Groffen, J.3
de Klein, A.4
Grosveld, G.5
-
3
-
-
0025348013
-
Tyrosine kinase activity and transformation potency of BCR-ABL oncogene products
-
Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of BCR-ABL oncogene products. Science 1990;247:1079-82.
-
(1990)
Science
, vol.247
, pp. 1079-1082
-
-
Lugo, T.G.1
Pendergast, A.M.2
Muller, A.J.3
Witte, O.N.4
-
4
-
-
0035810142
-
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
-
Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford R, Capdeville JM, Capdeville R, Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42.
-
(2001)
N Engl J Med
, vol.344
, pp. 1038-1042
-
-
Druker, B.J.1
Sawyers, C.L.2
Kantarjian, H.3
Resta, D.J.4
Reese, S.F.5
Ford, R.6
Capdeville, J.M.7
Capdeville, R.8
Talpaz, M.9
-
5
-
-
0037093092
-
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study
-
Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002;99:3530-9.
-
(2002)
Blood
, vol.99
, pp. 3530-3539
-
-
Sawyers, C.L.1
Hochhaus, A.2
Feldman, E.3
-
6
-
-
67349233062
-
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
-
Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009;23:1054-61.
-
(2009)
Leukemia
, vol.23
, pp. 1054-1061
-
-
Hochhaus, A.1
O'Brien, S.G.2
Guilhot, F.3
-
7
-
-
1242307298
-
Prognosis in childhood and adult acute lymphoblastic leukaemia: a question of maturation?
-
Plasschaert SL, Kamps WA, Vellenga E, de Vries EG, de Bont ES. Prognosis in childhood and adult acute lymphoblastic leukaemia: a question of maturation? Cancer Treat Rev 2004;30:37-51.
-
(2004)
Cancer Treat Rev
, vol.30
, pp. 37-51
-
-
Plasschaert, S.L.1
Kamps, W.A.2
Vellenga, E.3
de Vries, E.G.4
de Bont, E.S.5
-
8
-
-
64049089054
-
Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation
-
Bachanova V, Verneris MR, DeFor T, Brunstein CG, Weisdorf DJ. Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation. Blood 2009;113:2902-5.
-
(2009)
Blood
, vol.113
, pp. 2902-2905
-
-
Bachanova, V.1
Verneris, M.R.2
DeFor, T.3
Brunstein, C.G.4
Weisdorf, D.J.5
-
9
-
-
76349087390
-
Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
-
Wendy Stock.
-
Wendy Stock. Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Leuk Lymphoma 2010;51:188-98.
-
(2010)
Leuk Lymphoma
, vol.51
, pp. 188-198
-
-
-
10
-
-
42449165060
-
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia
-
Steelman LS, Abrams SL, Whelan J, et al. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 2008;22:686-707.
-
(2008)
Leukemia
, vol.22
, pp. 686-707
-
-
Steelman, L.S.1
Abrams, S.L.2
Whelan, J.3
-
11
-
-
32044465506
-
TOR signaling in growth and metabolism
-
Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006;124:471-84.
-
(2006)
Cell
, vol.124
, pp. 471-484
-
-
Wullschleger, S.1
Loewith, R.2
Hall, M.N.3
-
12
-
-
0025117392
-
Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome
-
Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990;247:824-30.
-
(1990)
Science
, vol.247
, pp. 824-830
-
-
Daley, G.Q.1
Van Etten, R.A.2
Baltimore, D.3
-
13
-
-
16844366670
-
ABLOncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors
-
Kharas MG, Fruman DA. ABLOncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors. Cancer Res 2005;65:2047-53.
-
(2005)
Cancer Res
, vol.65
, pp. 2047-2053
-
-
Kharas, M.G.1
Fruman, D.A.2
-
14
-
-
14644425319
-
Mechanisms of BCR-ABL the pathogenesis of chronic myelogenous leukaemia
-
Ren R. Mechanisms of BCR-ABL the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005;5:172-84.
-
(2005)
Nat Rev Cancer
, vol.5
, pp. 172-184
-
-
Ren, R.1
-
15
-
-
66149164593
-
Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies
-
Teachey DT, Grupp SA, Brown VI. Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. Br J Haematol 2009;145:569-80.
-
(2009)
Br J Haematol
, vol.145
, pp. 569-580
-
-
Teachey, D.T.1
Grupp, S.A.2
Brown, V.I.3
-
16
-
-
1542327671
-
Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs
-
Mohi MG, Boulton C, Gu TL. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci 2004;101:3130-5.
-
(2004)
Proc Natl Acad Sci
, vol.101
, pp. 3130-3135
-
-
Mohi, M.G.1
Boulton, C.2
Gu, T.L.3
-
17
-
-
77950069222
-
mTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein
-
Mancini M, Corradi V, Pettaa S, Martinelli G, Barbieri E, Santucci MA. mTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein. Leuk Res 2010;34:641-8.
-
(2010)
Leuk Res
, vol.34
, pp. 641-648
-
-
Mancini, M.1
Corradi, V.2
Pettaa, S.3
Martinelli, G.4
Barbieri, E.5
Santucci, M.A.6
-
18
-
-
51349108718
-
Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells
-
Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM, Fruman DA. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J Clin Invest 2008;118:3038-50.
-
(2008)
J Clin Invest
, vol.118
, pp. 3038-3050
-
-
Kharas, M.G.1
Janes, M.R.2
Scarfone, V.M.3
Lilly, M.B.4
Knight, Z.A.5
Shokat, K.M.6
Fruman, D.A.7
-
19
-
-
58549116685
-
Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: possible clinical application of mTOR inhibitor
-
Hirase C, Maeda Y, Takai S, Kanamaru A. Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: possible clinical application of mTOR inhibitor. Leuk Res 2009;33:450-9.
-
(2009)
Leuk Res
, vol.33
, pp. 450-459
-
-
Hirase, C.1
Maeda, Y.2
Takai, S.3
Kanamaru, A.4
-
20
-
-
84864064318
-
The mTOR inhibitor, everolimus (RAD001), overcomes resistance to imatinib in quiescent Ph-positive acute lymphoblastic leukemia cells
-
Kuwatsuka Y, Minami M, Minami Y, Sugimoto K, Hayakawa F, Miyata Y, Abe A, Goff DJ, Kiyoi H, Naoe T. The mTOR inhibitor, everolimus (RAD001), overcomes resistance to imatinib in quiescent Ph-positive acute lymphoblastic leukemia cells. Blood Cancer J. 2011;1(5):e17.
-
(2011)
Blood Cancer J.
, vol.1
, Issue.5
-
-
Kuwatsuka, Y.1
Minami, M.2
Minami, Y.3
Sugimoto, K.4
Hayakawa, F.5
Miyata, Y.6
Abe, A.7
Goff, D.J.8
Kiyoi, H.9
Naoe, T.10
-
21
-
-
84866267909
-
Antileukaemia effect of rapamycin alone or in combination with daunorubicin on ph+ acute lymphoblastic leukaemia cell line
-
Yang X, Lin J, Gong Y, Ma H, Shuai X, Zhou R, Guo Y, Shan Q, He G. Antileukaemia effect of rapamycin alone or in combination with daunorubicin on ph+ acute lymphoblastic leukaemia cell line. Hematol Oncol 2012;30:123-30.
-
(2012)
Hematol Oncol
, vol.30
, pp. 123-130
-
-
Yang, X.1
Lin, J.2
Gong, Y.3
Ma, H.4
Shuai, X.5
Zhou, R.6
Guo, Y.7
Shan, Q.8
He, G.9
-
22
-
-
84868348363
-
Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway
-
Guo Y, Shan Q, Gong Y, Lin J, Yang X, Zhou R. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway. Cancer Biol Ther 2012;13:1244-54.
-
(2012)
Cancer Biol Ther
, vol.13
, pp. 1244-1254
-
-
Guo, Y.1
Shan, Q.2
Gong, Y.3
Lin, J.4
Yang, X.5
Zhou, R.6
-
23
-
-
43049101649
-
Two hour exposure to sodium butyrate sensitizes bladder cancer to anticancer drugs
-
Wang DG, Wang ZP, Tian BQ, Li X, Li S, Tian Y. Two hour exposure to sodium butyrate sensitizes bladder cancer to anticancer drugs. Int J Urol 2008;15:435-41.
-
(2008)
Int J Urol
, vol.15
, pp. 435-441
-
-
Wang, D.G.1
Wang, Z.P.2
Tian, B.Q.3
Li, X.4
Li, S.5
Tian, Y.6
-
24
-
-
75749122303
-
Methods in mammalian autophagy research
-
Mizushima N, Yoshimori T, Levine B. Methods in mammalian autophagy research. Cell 2010;140:313-26.
-
(2010)
Cell
, vol.140
, pp. 313-326
-
-
Mizushima, N.1
Yoshimori, T.2
Levine, B.3
-
25
-
-
74949100074
-
RAD001 (Everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia
-
Mancini M, Petta S, Martinelli G, Barbieri E, Santucci MA. RAD001 (Everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia. J Cell Biochem 2010;109:320-8.
-
(2010)
J Cell Biochem
, vol.109
, pp. 320-328
-
-
Mancini, M.1
Petta, S.2
Martinelli, G.3
Barbieri, E.4
Santucci, M.A.5
-
26
-
-
27144526660
-
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development
-
Burchert A, Wang Y, Cai D. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia 2005;19:1774-82.
-
(2005)
Leukemia
, vol.19
, pp. 1774-1782
-
-
Burchert, A.1
Wang, Y.2
Cai, D.3
-
27
-
-
76349109033
-
Novel pathway in BCR-ABL signal transduction involves Akt-independent, PLC-γ1-driven activation of mTOR/ p70S6-kinase pathway
-
Markova B, Albers C, Breitenbuecher F, Melo JV, Brümmendorf TH, Heidel F, Lipka D, Duyster J, Huber C, Fischer T. Novel pathway in BCR-ABL signal transduction involves Akt-independent, PLC-γ1-driven activation of mTOR/ p70S6-kinase pathway. Oncogene 2010;29:739-51.
-
(2010)
Oncogene
, vol.29
, pp. 739-751
-
-
Markova, B.1
Albers, C.2
Breitenbuecher, F.3
Melo, J.V.4
Brümmendorf, T.H.5
Heidel, F.6
Lipka, D.7
Duyster, J.8
Huber, C.9
Fischer, T.10
-
28
-
-
42449146501
-
Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy
-
McCubrey JA, Steelman LS, Abrams SL, et al. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 2008;22:708-22.
-
(2008)
Leukemia
, vol.22
, pp. 708-722
-
-
McCubrey, J.A.1
Steelman, L.S.2
Abrams, S.L.3
-
29
-
-
34147146014
-
Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML
-
Zeng Z, Sarbassov dos D, Samudio IJ, Yee KW, Munsell MF, Ellen Jackson C, Giles FJ, Sabatini DM, Andreeff M, Konopleva M. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 2007;109:3509-12.
-
(2007)
Blood
, vol.109
, pp. 3509-3512
-
-
Zeng, Z.1
Sarbassov dos, D.2
Samudio, I.J.3
Yee, K.W.4
Munsell, M.F.5
Ellen Jackson, C.6
Giles, F.J.7
Sabatini, D.M.8
Andreeff, M.9
Konopleva, M.10
-
30
-
-
20844448882
-
Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species
-
Kim JH, Chu SC, Gramlich JL, Pride YB, Babendreier E, Chauhan D, Salgia R, Podar K, Griffin JD, Sattler M. Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood 2005;105:1717-23.
-
(2005)
Blood
, vol.105
, pp. 1717-1723
-
-
Kim, J.H.1
Chu, S.C.2
Gramlich, J.L.3
Pride, Y.B.4
Babendreier, E.5
Chauhan, D.6
Salgia, R.7
Podar, K.8
Griffin, J.D.9
Sattler, M.10
-
31
-
-
46149092748
-
Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment
-
Jiang BH, Liu LZ. Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist Updat 2008;11:63-76.
-
(2008)
Drug Resist Updat
, vol.11
, pp. 63-76
-
-
Jiang, B.H.1
Liu, L.Z.2
-
32
-
-
37649005234
-
Autophagy in the pathogenesis of disease
-
Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008;132:27-42.
-
(2008)
Cell
, vol.132
, pp. 27-42
-
-
Levine, B.1
Kroemer, G.2
-
33
-
-
70349638918
-
Targeted therapies and autophagy: new insights from chronic myeloid leukemia
-
Salomoni P, Calabretta B. Targeted therapies and autophagy: new insights from chronic myeloid leukemia. Autophagy 2009;5:1050-1.
-
(2009)
Autophagy
, vol.5
, pp. 1050-1051
-
-
Salomoni, P.1
Calabretta, B.2
-
34
-
-
70349644004
-
Autophagy facilitates oncogene-induced senescence
-
Narita M, Young AR, Narita M. Autophagy facilitates oncogene-induced senescence. Autophagy 2009;5:1046-7.
-
(2009)
Autophagy
, vol.5
, pp. 1046-1047
-
-
Narita, M.1
Young, A.R.2
Narita, M.3
-
37
-
-
34548188741
-
Self-eating and self-killing: crosstalk between autophagy and apoptosis
-
Maiuri MC, Zalckvar E, Kimchi A, Kroemer G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nature 2007;8:741-52.
-
(2007)
Nature
, vol.8
, pp. 741-752
-
-
Maiuri, M.C.1
Zalckvar, E.2
Kimchi, A.3
Kroemer, G.4
-
38
-
-
48249092267
-
Bcl-2 family members: dual regulators of apoptosis and autophagy
-
Levine B, Sinha S, Kroemer G. Bcl-2 family members: dual regulators of apoptosis and autophagy. Autophagy 2008;4:600-6.
-
(2008)
Autophagy
, vol.4
, pp. 600-606
-
-
Levine, B.1
Sinha, S.2
Kroemer, G.3
-
39
-
-
84865708324
-
Apoptosis and autophagy have opposite roles on imatinib-induced K562 leukemia cell senescence
-
Drullion C, Tregoat C, Lagarde V. Apoptosis and autophagy have opposite roles on imatinib-induced K562 leukemia cell senescence. Cell Death Dis 2012;3:e373.
-
(2012)
Cell Death Dis
, vol.3
-
-
Drullion, C.1
Tregoat, C.2
Lagarde, V.3
-
40
-
-
33746637660
-
Current development of mTOR inhibitors as anticancer agents
-
Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discovery 2006;5:671-88.
-
(2006)
Nat Rev Drug Discovery
, vol.5
, pp. 671-688
-
-
Faivre, S.1
Kroemer, G.2
Raymond, E.3
-
41
-
-
70349322878
-
Rapamycin, the mTOR kinase inhibitor, sensitizes acute myeloid leukemia cells, HL-60 cells, to the cytotoxic effect of arabinozide cytarabine
-
Janusa A, Linkea A, Cebula B, Robak T, Smolewski P. Rapamycin, the mTOR kinase inhibitor, sensitizes acute myeloid leukemia cells, HL-60 cells, to the cytotoxic effect of arabinozide cytarabine. Anticancer Drug 2009;20:693-701.
-
(2009)
Anticancer Drug
, vol.20
, pp. 693-701
-
-
Janusa, A.1
Linkea, A.2
Cebula, B.3
Robak, T.4
Smolewski, P.5
|